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BACKGROUND: Patients with cancer are considered at high risk for the novel respiratory illness coronavirus disease 2019 (COVID-19). 
General measures to keep COVID-19–free cancer divisions have been adopted worldwide. The objective of this study was to evaluate the 
efficacy of triage to identify COVID-19 among patients with cancer. METHODS: From March 20 to April 17, 2020, data were collected 
from patients who were treated or followed at the authors’ institution in a prospective clinical trial. The primary endpoint was to esti-
mate the cumulative incidence of COVID-19–positive patients who were identified using a triage process through the aid of medical and 
patient questionnaires. Based on a diagnostic algorithm, patients with suspect symptoms underwent an infectious disease specialist’s 
evaluation and a COVID-19 swab. Serologic tests were proposed for patients who had symptoms or altered laboratory tests that did not 
fall into the diagnostic algorithm but were suspicious for COVID-19. RESULTS: Overall, 562 patients were enrolled. Six patients (1%) were 
diagnosed with COVID-19, of whom 4 (67%) had the disease detected through telehealth triage, and 2 patients (33%) without suspect 
symptoms at triage had the disease detected later. Seventy-one patients (13%) had suspect symptoms and/or altered laboratory tests 
that were not included in the diagnostic algorithm and, of these, 47 patients (73%) underwent testing for severe acute respiratory syn-
drome coronavirus 2 antibody: 6 (13%) were positive for IgG (n = 5) or for both IgM and IgG (n = 1), and antibody tests were negative in 
the remaining 41 patients. CONCLUSIONS: The triage process had a positive effect on the detection of COVID-19 in patients with cancer. 
Telehealth triage was helpful in detecting suspect patients and to keep a COVID-19–free cancer center. The overall incidence of COVID-19 
diagnosis (1%) and antibody positivity (13%) in patients with suspect symptoms was similar to that observed in the general population. 
Cancer 2020;0:1-11. © 2020 American Cancer Society. 
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INTRODUCTION
Worldwide, health services are facing the challenge of the severe acute respiratory syndrome coronavirus 2 (SARS– 
CoV-2) pandemic.1 The most common symptoms of the novel respiratory illness coronavirus disease 2019 (COVID-19) 
are fever, cough, and dyspnea; but myalgias, diarrhea, headache, cutaneous manifestations, sore throat, ageusia, and an-
osmia have also been reported. Although most patients present with mild symptoms, in a subset of infected individuals, 
patients worsen to pneumonia, multiorgan failure, and eventually die. As of June 2020, COVID-19 has spread to >200 
countries worldwide, with >9.2 million affected individuals; the number of confirmed deaths is >475,000.2 After China, 
Italy was the second country to experience the rapid spread of COVID-19. In Italy, the pandemic initially affected the 
Lombardy region, especially Milan, where our hospital is located; it had higher lethality here than in China and worldwide.3
Patients with immunocompromised status, like those who have cancer, are at high risk of infection. Cancer devel-
ops in an immunocompromised field, and oncologic treatments (eg, chemotherapy, radiotherapy) can increase the risk 
of infection.4,5 Medical oncologists have changed their daily clinical practice in view of the current emergency6 with the 
aid of rapidly drafted guidelines for patient management during the pandemic.7 However, the limited data have not 
led to evidence-based recommendations. Evidence suggests that COVID-19 diffusion in patients with cancer is not as 
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prominent as expected; however, mortality seems to be 
higher than that reported for the general population and 
correlates with general risk factors as well as those unique 
to patients with cancer.8-12 Indeed, other comorbidities 
(eg, cardiovascular disease, diabetes, chronic obstructive 
pulmonary disease) correlate with a higher risk of infec-
tion and severe events.13
Most treatment procedures in oncology cannot be 
delayed without compromising the efficacy of treatment 
itself. To guarantee the provision of oncology services, 
general measures to keep cancer centers COVID-free 
have been adopted, for example, the use of protective 
devices, patient triage with on-site temperature evalu-
ation, and questions regarding contact and travel his-
tory in high-risk areas before accessing the hospital.14 
Telehealth has replaced follow-up for nonurgent visits. 
Telehealth has also been used to avoid allowing patients 
with fever and/or recent-onset respiratory symptoms 
access to oncology services, with redirection to general 
practitioners for home care or, whenever required, to 
hospitalization.14
However, fever and/or respiratory symptoms can be 
very common findings in patients with cancer, and the 
interpretation of such symptoms in these patients can 
be challenging because they are potentially attributed to 
the seasonal flu, COVID-19, or may simply relate to the 
underlying disease and/or ongoing systemic treatment. 
In light of the need for appropriate resource allocation, 
the objective of our current study was to evaluate the fre-
quency of COVID-19–like symptoms in patients with 
cancer and to identify high-risk patients to be evaluated 
for COVID-19 infection by using a diagnostic and deci-
sional algorithm.
MATERIALS AND METHODS
This study was approved by our Institutional Review 
Board. The primary endpoint was to estimate the cumu-
lative incidence of COVID-19–positive patients identi-
fied by triage. The exploratory endpoint was to create a 
diagnostic and decisional algorithm for patients with sus-
pected COVID-19.
We prospectively collected data from all patients 
who were treated or followed at our institution from 
March 20 to April 17, 2020. Institutional guidelines, sup-
ported by the Italian Association of Medical Oncology 
(Associazione Italiana di Oncologia Medica), indicated 
rescheduling nonurgent visits. Telehealth visits replaced 
in-person visits. All patients accessing the hospital gave 
their written informed consent for the use of clinical data 
for scientific purposes, whereas those undergoing tele-
health visits gave their verbal agreement to participate, 
and informed consent was signed during their earliest 
in-person visit.
Patients’ baseline characteristics and data regarding 
cancer treatment were collected. Patients were triaged 
using 2 paper questionnaires. Questionnaire 1 was com-
pleted by physicians in direct patient interviews and as-
sessed the following items: performance status (according 
to the Eastern Cooperative Oncology Group scale), fever 
and/or COVID-19–like respiratory and nonrespiratory 
symptoms in the previous 30 days, thoracic examination, 
and previous or ongoing thoracic radiotherapy. A full 
version of the questionnaire is provided in Supporting 
Table 1.
Questionnaire 2 was completed by patients at 
the hospital and assessed the following items: smoking 
history; concomitant receipt of corticosteroids, acet-
aminophen, and antibiotics plus insulin and oxygen 
therapy and a possible recent increase in daily need of 
these treatments; respiratory illnesses (asthma, chronic 
obstructive pulmonary disease, emphysema); a history 
of pleuritis and/or pneumonitis; recent vaccinations 
(seasonal flu, pneumococcal); fever and/or respiratory 
symptoms in patients and close contacts (household, 
friends); and travel to high-risk areas within the previ-
ous 15 days. A full version of the patient questionnaire 
is provided in Supporting Table 2.
Vital signs (blood pressure, heart rate, blood oxygen 
saturation, and respiratory rate) were recorded by nurses 
before treatment administration; body temperature was 
measured with a digital, contactless, infrared thermometer. 
Pretreatment blood tests included complete blood count, 
lactate dehydrogenase, and C-reactive protein (CRP).
The diagnostic algorithm for patients with sus-
pected COVID-19 came from recommendations of na-
tional guidelines and data from the literature available 
at the beginning of the pandemic.15-17 An infectious 
disease specialist’s evaluation was promptly performed 
when the triage process and the medical question-
naire detected fever and new-onset respiratory symp-
toms; chest imaging and a SARS–CoV-2 swab were 
performed if clinically indicated (Fig. 1). Through the 
subsequent analysis of the questionnaires, patients were 
followed for symptom evolution. SARS–CoV-2 rapid 
tests (Beijing LEPU Medical Technology Company, 
Ltd) were offered to patients who reported suspect signs 
or symptoms that did not fall into the diagnostic algo-
rithm (SARS–CoV-2 IgM and IgG: sensitivity, 88.7%; 
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specificity, 90.6%).18 Patients who were positive for 
IgM and/or IgG on rapid tests underwent chemilumi-
nescence immunoassays (CLIAs) (LIAISON [Diasorin 
SpA] and MAGLUMI [Snibe Diagnostics, Shenzhen 
New Industries Biomedical Engineering Company, 
Ltd]. LIAISON is an indirect test detecting IgG against 
the subunits S1 and S2 of the spike viral proteins 
(specificity, approximately 98%; sensitivity, 25% at <5 
days, 90.4% at 5-15 days, and 97.4% at >15 days from 
the onset of symptoms). A negative result is defined by 
an IgG level <15 AU/mL, whereas a positive result is 
defined as an IgG level ≥15 AU/mL.19-21 MAGLUMI 
is a CLIA for IgM and IgG against SARS–CoV-2 
S-antigen and N-protein (IgM and IgG sensitivity, 78% 
Figure 1. This is the algorithm used for the management of patients with cancer who presented with signs and symptoms suspicious 
for coronavirus disease 2019 (COVID-19). BT indicates body temperature; CT, computed tomography.
Figure 2. This is a flow diagram of the enrolled patients. *In group C, 68 outpatient on-treatment visits were included (for complete 
details, refer to the text).
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and 91%, respectively; IgM and IgG specificity, 97%; 
combined IgM and IgG sensitivity, 89.9%-95.6%; IgM 
and IgG specificity, 96.5%-96.0%). The IgM and IgG 
cutoff levels for positive tests were 1.0 and 1.1 AU/mL, 
respectively.22-24 Patients with positive CLIA serology 
underwent rhinopharyngeal swabs for SARS–CoV-2.
To evaluate the role of symptoms and to identify the in-
cidence of SARS–CoV-2 positivity in asymptomatic patients, 
we performed a case-control (1:1) comparison. Serologic 
tests were performed in patients with known COVID-19 to 
verify the serology in the case of documented infection.
Patients who were included in the current study were 
followed for COVID-19 onset. Data regarding specific 
characteristics of the infection were prospectively col-
lected in a dedicated database in the case of documented 
SARS–CoV-2 infection.
TABLE 1. General Characteristics of the Study Population
Characteristic
No. (%)
All Patients,  
N = 562
Group A: Telehealth Visits,  
n = 193
Group B: Outpatient Visits,  
n = 108
Group C: Day Hospital 
Visits, n = 261
Age: Median [range], y 69 [26-94] 69 [36-94] 66 [31-88] 69 [26-91]
City of residence
Milan 375 (67) 140 (73) 72 (67) 163 (62)
Milan district 106 (19) 27 (14) 19 (17) 60 (23)
Othera 81(14) 26 (13) 17 (16) 38 (15)
Sex
Men 196 (35) 58 (30) 43 (40) 95 (36)
Women 366 (65) 135 (70) 65 (60) 166 (64)
Ethnicity
Caucasian 527 (94) 187 (97) 99 (92) 241 (92)
Asiatic 19 (3) 3 (2) 5 (4) 11 (4)
Hispanic 9 (2) 1 (<1) 4 (4) 4 (2)
African 7 (1) 2 (1) — 5 (2)
Cancer diagnosisb
Thoracic 138 (25) 25 (13) 23 (21) 90 (35)
Breast 207 (37) 96 (50) 28 (26) 83 (32)
GI tract 118 (21) 48 (24) 26 (24) 44 (17)
Head and neck 11 (2) — 3 (3) 8 (3)
Pancreas and biliary tract 33 (6) 9 (5) 8 (7) 16 (6)
Skin: Melanoma, 
nonmelanoma
18 (3) 5 (3) 7 (7) 6 (2)
Genitourinary tract 23 (4) 5 (3) 8 (7) 10 (4)
Other 14 (2) 5 (2) 5 (5) 4 (1)
Active treatment
Yes 344 (61) 58 (30) 25 (23) 261 (100)
No, follow-up 218 (39) 135 (70) 83 (77) —
Type of treatment
Chemo 126 (37) 3 (5) 5 (20) 118 (45)
Immunotherapy 46 (13) 1 (2) 1 (4) 44 (17)
Chemo and immunotherapy 12 (4) — — 12 (5)
Chemo and biologic 
agentsc
38 (11) 2 (3) 1 (4) 35 (13)
Otherd 122 (35) 52 (90) 18 (72) 52 (20)
Treatment administration
Intravenous 185 (53) 5 (8) 4 (16) 176 (67)
Oral 112 (32) 48 (83) 20 (80) 44 (17)
Intravenous and oral 21 (6) — 1 (4) 20 (8)
Intramuscular and oral 18 (5) 4 (7) — 14 (5)
Intramuscular/
subcutaneous
8 (2) 1 (2) — 7 (3)
Line of treatment
Adjuvant/neoadjuvant 119 (35) 52 (90) 17 (68) 50 (19)
1 129 (37) 5 (8) 5 (20) 119 (46)
2 57 (17) 1 (2) 1 (4) 55 (21)
≥3 39 (11) — 2 (8) 37 (14)
Abbreviations: Chemo, chemotherapy; GI, gastrointestinal.
aOther indicates the remaining geographic areas outside of the Milan district.
bSix patients (1%) had second primary cancers.
cThese include the following monoclonal antibodies: antivascular endothelial growth factor, antiepidermal growth factor receptor, and antihuman epidermal growth 
factor receptor 2.
dThese include the following treatments: cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitors, hormonal treatment, oral targeted agents (eg, tyrosine kinase inhibi-
tors, mitogen-activated pathway kinase inhibitors), and somatostatin analogues.
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Statistical Analysis
Basic descriptive statistics were used to describe the popu-
lation. Differences in categorical variables were analyzed 
using the Fisher exact test. The chi-square test was used 
to analyze proportions when appropriate (comparing 3 
groups). Odds ratios and 95% CIs were calculated for each 
comparison. The t test and the Mann-Whitney test were 
used to compare continuous variables, as appropriate. P val-
ues <.05 were considered statistically significant. Statistical 
analysis was performed using GraphPad Prism version 6.0 
(GraphPad Software Inc) and IBM-Microsoft SPSS version 
20.0 (SPSS Statistics, IBM Inc) for Mac (Apple Inc).
TABLE 2. Items Assessed in Questionnaire 1 (Completed by Medical Oncologists)
Item
No. (%)
All Patients,  
N = 562
Group A: Telehealth Visits,  
n = 193
Group B: Outpatient Visits,  
n = 108
Group C: Day Hospital 
Visits, n = 261
ECOG PS
0 350 (62) 150 (78) 63 (58) 137 (53)
1 168 (30) 33 (17) 35 (33) 100 (38)
≥2 44 (8) 10 (5) 10 (9) 24 (9)
History of thoracic RT
Yes 75 (13) 27 (14) 24 (22) 24 (9)
No 487 (87) 166 (86) 84 (78) 237 (91)
Fever
Yes 22 (4) 6 (3) 4 (4) 12 (5)
No 540 (96) 187 (97) 104 (96) 249 (95)
Symptoms
Yes 138 (25) 12 (6) 20 (18) 106 (41)
No 424 (75) 181 (94) 88 (82) 155 (59)
COVID-19–like respiratory 
symptoms
30 (22) — 4 (20) 26 (24)
Dyspnea 17 (57) — 3 (75) 14 (54)
Stable 10 (59) — 3 (100) 9 (64)
Worsened 7 (41) — — 5 (36)
Cough 9 (30) — — 9 (35)
Stable 3 (33) — — 6 (67)
Worsened 6 (67) — — 3 (33)
Dyspnea and cough 4 (13) — 1 (25) 3 (11)
Stable 4 (100) — 1 (100) 3 (100)
Worsened — — — —
COVID-19–like nonrespiratory 
symptomsa
68 (49) 6 (50) 8 (40) 54 (51)
Fatigue 47 (69) 1 (17) 4 (50) 42 (78)
Stable 42 (89) 1 (100) 4 (100) 37 (88)
Worsened 5 (11) — — 5 (12)
Myalgias 7 (10) — — 7 (13)
Stable 2 (29) — — 5 (71)
Worsened 5 (71) — — 2 (29)
Conjunctivitis 8 (12) — 1 (12) 7 (13)
Stable 4 (50) — — 4 (57)
Worsened 4 (50) — 1 (100) 3 (43)
Rhinitis/pharyngodinia 6 (9) 2 (33) 2 (25) 2 (4)
Stable 2 (33) 1 (50) 1 (50) 1 (50)
Worsened 4 (67) 1 (50) 1 (50) 1 (50)
GI symptomsb 7 (10) 1 (17) 1 (12) 5 (9)
Stable 5 (71) 1 (100) — 4 (80)
Worsened 2 (29) — 1 (100) 1 (20)
Otherc 3 (4) 2 (33) 1 (12) 2 (4)
COVID-19–like respiratory and 
nonrespiratory symptoms
40 (29) 6 (50) 8 (42) 26 (24)
Dyspnea and other symptoms 18 (45) 3 (50) 4 (50) 11 (42)
Cough and other symptoms 14 (35) 3 (50) 2 (25) 9 (35)
Dyspnea, cough, and other 
symptomsc
8 (20) — 2 (25) 6 (23)
Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; GI, gastrointestinal; PS, performance status; RT, radiotherapy.
aThese included patients with ≥1 symptom(s).
bGI symptoms included nausea (n = 5), vomiting (n = 2), diarrhea (n = 2), and decreased food intake (n = 1).
cThese included the following symptoms: headache (n = 4), chills (n = 3), anorexia (n = 1), cutaneous rash (n = 1), noncardiac chest pain (n = 1), anxiety (n = 1), 
malaise (n = 1), and ageusia (n = 1).
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RESULTS
Baseline Patient Characteristics
Overall, 675 patients were eligible for the study, 562 
patients were enrolled, and 113 patients were excluded. 
Figure 2 illustrates the flow of patients through the study 
period. Group A had 193 (34%) telehealth visits, group B 
had 108 (19%) outpatient ambulatory visits, and group 
C had 261 (47%) day hospital visits (including 68 outpa-
tient on-treatment visits).
Table 1 lists the baseline characteristics of the study 
population. The median age of patients was 69 years 
(range, 26-94 years), with a 1:1.8 male-to-female ratio. 
The most common cancer diagnosis was breast cancer 
(37%), followed by thoracic cancer (25%), and gastroin-
testinal tumors (18%). In total, 344 patients (61%) were 
receiving active anticancer treatment, including approxi-
mately 30% of patients in groups A and B and all patients 
in group C (P < .001). Most patients were receiving che-
motherapy (37%), followed by immunotherapy (13%), 
chemotherapy plus monoclonal antibodies (11%), or 
chemotherapy plus immunotherapy (4%); and 122 pa-
tients (35%) were receiving various anticancer agents (see 
Table 1). Most patients in groups A and B were receiving 
oral therapies (83% and 80%), and a minority of patients 
who were receiving intravenous treatment did not access 
the day hospital during the study period. Conversely, 117 
patients (45%) in group C were receiving intravenous 
chemotherapy, 44 (17%) were receiving immunother-
apy, 35 (13%) were receiving chemotherapy plus biologic 
agents, 12 (5%) were receiving chemotherapy plus im-
munotherapy, and 52 (20%) were receiving oral (17%) 
TABLE 3. Items Assessed in Questionnaire 2 (Completed by Patients)
Item
No. (%)
All Patients: Group B and C,  
N = 369
Group B: Outpatient Visits,  
n = 108
Group C: Day Hospital 
Visits, n = 261
Comorbidity(ies)a
None 176 (48) 52 (48) 124 (47)
1 97 (26) 25 (23) 72 (28)
2 57 (15) 17 (16) 40 (15)
≥3 39 (11) 14 (13) 25 (10)
Oxygen therapy
Yes 16 (4) 7 (6) 9 (3)
No 353 (96) 101 (94) 252 (97)
Seasonal flu vaccination
Yes 132 (36) 52 (48) 81 (31)
No 172 (47) 27 (25) 145 (56)
Missing data 65 (17) 29 (27) 35 (13)
Other vaccination(s)
Yes, antipneumococcal 5 (1) 3 (2) 2 (<1)
No 297 (81) 75 (69) 223 (85)
Not assessed 67 (18) 30 (28) 36 (14)
Smoking history
Smoker 46 (13) 12 (11) 34 (13)
Former smokerb 122 (33) 36 (33) 86 (33)
Never smoked 170 (46) 41 (38) 129 (49)
Unknown 31 (8) 19 (18) 12 (5)
Concomitant therapy(ies)
Corticosteroids 75 (20) 6 (5) 69 (26)
Acetaminophenc 77 (21) 17 (16) 60 (23)
Antibiotics 16 (4) 4 (4) 12 (5)
High-risk contacts
Yes 6 (1) 4 (4) 2 (1)
No 335 (91) 104 (96) 233 (89)
Unknown 28 (8) — 26 (10)
Fever
Yes 16 (4) 4 (4) 12 (5)
No 353 (96) 104 (96) 249 (95)
Symptoms
Yes 120 (32) 18 (17) 102 (39)
No 249 (68) 90 (83) 159 (61)
aRelevant comorbidities included the following: cardiovascular disease (ischemic heart disease, heart failure), hypertension, respiratory disease (asthma, pulmo-
nary emphysema, chronic obstructive pulmonary disease), diabetes, chronic infections (hepatitis B virus, hepatitis C virus, HIV infections), autoimmune conditions 
(including rheumatologic diseases), hematologic disease (chronic lymphocytic leukemia, multiple myeloma), and neurologic conditions (cerebrovascular disease).
bPatients were considered former smokers if smoking cessation happened ≥1 year ago.
cThese included patients receiving acetaminophen as needed.
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and intramuscular/subcutaneous therapy (3%). In group 
A, 90% of patients were receiving neoadjuvant/adjuvant 
treatment compared with 61% in group B and 19% in 
group C (P < .001). A higher proportion of patients in 
group C were receiving >2 lines of treatment (n = 92 
[35%]; P < .001).
Results of the Triage Process
The items assessed in questionnaire 1 are displayed 
in Table 2. Overall, 138 patients (25%) reported at 
least 1 symptom. Of these, 30 patients (22%) reported 
COVID-19–like respiratory symptoms, 68 (49%) re-
ported COVID-19–like nonrespiratory symptoms, and 
40 (29%) reported both respiratory and nonrespira-
tory symptoms. After excluding patients with preexist-
ing symptoms, 68 (49%) had new-onset or worsening 
COVID-19–like respiratory symptoms (n = 17; 25%), 
or nonrespiratory symptoms (n = 23; 34%), or both 
(n = 28; 41%). Twelve patients (2%) had increased CRP 
levels (ie, >10 times the upper limit of normal), either 
alone (n = 6) or with COVID-19–like symptoms (n = 6).
Table 3 displays the answers to questionnaire 2. 
The overall completion rate was 89%. In group B, 48% 
of patients had no comorbidities; whereas 23%, 16%, 
and 13% had 1, 2, and ≥3 comorbidities, respectively. 
In group C, 47% of patients had no comorbidities; 
whereas 28%, 15%, and 10% had 1, 2, and ≥3 comor-
bidities, respectively. Forty-eight percent of patients in 
group B and 31% of those in group C received seasonal 
flu vaccination (P < .001). Most patients were former 
smokers (33% in both groups) or never smokers (38% 
in group B, 49% in group C); and 11% and 13% of 
patients were smokers in group B and C, respectively (P 
= .586). Compared with group B, a higher proportion 
of patients in group C were receiving ongoing cortico-
steroid therapy (26% vs 5%; P < .001), and a slightly 
(not significant) higher proportion were receiving on-
going acetaminophen therapy (23% vs 16%; P = .119). 
A minority of patients were receiving ongoing antibi-
otic therapy (4% vs 5%; P = .701). Overall, 94% of 
patients in group B and 88% in group C did not report 
high-risk contacts (P = .063). Fever was an uncommon 
finding: 96% of patients in group B and 95% in group 
C did not report fever within 30 days before completing 
the questionnaires. Similarly, the proportion of patients 
without suspect symptoms was 83% in group B and 
61% in group C (P < .001).
Blood tests showed a neutrophil-to-lymphocyte 
ratio ≥5 in 25 patients (10%; mean ± SD, 2.8 ± 3.3); 
and CRP and lactate dehydrogenase levels were within 
the reference interval in 171 (66%) and 185 (71%) of 
patients, respectively. All patients had a body temperature 
<37 °C (mean ± SD, 36 °C ± 0.35 ° C) and had adequate 
blood oxygen saturation (mean ± SD, 97% ± 1.8%). The 
mean ± SD respiratory rate was 16 ± 5 breaths per min-
ute, and a higher rate was observed in patients who had 
thoracic primary or secondary tumors and was not further 
investigated. No medical intervention was required based 
on vital signs. The results of laboratory analyses and vital 
signs are detailed in Table 4.
Based on the medical questionnaires, 4 patients 
(<1%) met the algorithm criteria (3 telehealth triages 
and 1 ambulatory visit), and all had a COVID-19 di-
agnosis. Two patients (<1%) had a negative triage (1 in 
group B, 1 in group C) and developed fever and respi-
ratory symptoms after 20 and 30 days from triage eval-
uation, respectively. These 2 patients subsequently were 
diagnosed with COVID-19. Based on patients’ question-
naires, no patients met the algorithm criteria to be tested 
for COVID-19. Patients who reported at least 1 symptom 
at the questionnaire and/or altered laboratory tests were 
followed and selected for serologic tests.
TABLE 4. Laboratory Analysis and Vital Signs
Variable
Group C: Day Hospital 
Visits, n = 261
CRP, mg/dL
Mean ± SD 1.02 ± 1.9
Median [range] 0.28 [0.01-11.51]
No. (%)
<ULN 171 (66)
≥ULN to ≤ULN × 3 43 (16)
>3 × ULN to ≤5 × ULN 16 (6)
>5 × ULN to ≤10 × ULN 19 (7)
>10 × ULN 12 (5)
NLR ratio
Mean ± SD 2.8 ± 3.3








Mean ± SD 36 ± 0.35
Median [range] 36 [34.6-36.2]
SpO2, %
Mean ± SD 97 ± 1.8
Median [range] 98 [95-100]
Respiration rate, bpm
Mean ± SD 16 ± 5
Median [range] 15 [10-25]
Abbreviations: bpm, breaths per minute; CRP, C-reactive protein; LDH, lac-
tate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; SpO2, blood oxy-
gen saturation; ULN, upper limit of normal.
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Results of Serologic Tests
Figure 3 illustrates the flow of patients selected for sero-
logic tests. Of the 74 patients who had new-onset symp-
toms and/or altered laboratory tests, 47 (63%) underwent 
rapid SARS–CoV-2 IgM/IgG tests. The remaining pa-
tients (n = 27; 37%) were not tested based on the pa-
tient’s refusal (n = 12), poor performance status (n = 7), 
hospitalization (n = 3), or death (n = 5).
The control group included 47 asymptomatic pa-
tients. Table 5 displays the characteristics of patients un-
dergoing serologic tests. Among the patients who were 
screened with the LEPU test, 6 (13%) were positive, includ-
ing 4 who were IgG-positive, 1 who was IgM-positive, and 
1 who was both IgM-positive and IgG-positive. IgG posi-
tivity was confirmed in 4 of 5 patients who were screened 
with the LIAISON test and in 2 of 5 patients who were 
screened with the MAGLUMI test (2 patients had border-
line positive values); all MAGLUMI tests were negative for 
IgM. In the control group, 5 patients (11%) had a positive 
LEPU test, including 2 who were IgM-positive (weak), 1 
who was IgG-positive, 1 who was IgG-positive (weak), and 
1 who was both IgM-positive and IgG-positive. LIAISON 
and MAGLUMI tests confirmed IgG positivity in 1 IgG-
positive patient and in 1 IgM-positive/IgG-positive patient; 
all MAGLUMI tests were negative for IgM. The prevalence 
of an IgM-positive/IgG-positive result using the LEPU test 
was similar between patients with symptoms and the con-
trol group (13% vs 11%; P = .748).
All patients who had positive LEPU tests and/or 
CLIAs underwent rhinopharyngeal swabs at a median 
of 40 days (range, 35-45 days) after questionnaire com-
pletion, and all were negative except for 1 patient in the 
control group.
DISCUSSION
The ONCOVID study is the first prospective study col-
lecting data from patients with cancer at the beginning 
of the COVID-19 outbreak using a structured triage 
process. From the time of study conception throughout 
the period of data collection, the number of COVID-
19 cases increased from 22,000 to 63,000 in Lombardy 
and from 1550 to 6300 in the city of Milan.6,25,26 
Therefore, the need for a triage process for oncology fa-
cilities rapidly became essential for our clinical practice. 
The results of our study suggest that triage can be useful 
for detecting COVID-19 symptoms and signs without 
being associated with false-positive or false-negative 
results. Telehealth triage seems to help with detecting 
suspect patients and keeping a COVID-19–free cancer 
center.
Data on COVID-19 and cancer are growing rap-
idly. Most prospective studies, however, have focused on 
patients who have cancer with a confirmed COVID-19 
Figure 3. This is a flow diagram of symptomatic patients or patients with altered laboratory tests who were selected for coronavirus 
disease 2019 (COVID-19) serologic tests. CRP indicates C-reactive protein; PS, performance status; BSC, best supportive care.
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diagnosis (either clinical, radiologic, or performed with 
serologic tests/rhinopharyngeal swabs).27-29 Overall, 
there does not appear to be a higher incidence of 
COVID-19 in patients with cancer, and the risk does 
not seem to be increased in those receiving anticancer 
treatment. Still, patients with cancer seem to be at higher 
risk of severe COVID-19 and reduced intensive care 
unit access, leading to higher mortality rates. In a recent 
report from the National Cancer Institute of Milan, a 
triage process, consisting of high-resolution, low-dose 
computed tomography thoracic scans followed by a rhi-
nopharyngeal swab, was used to detect SARS–CoV-2 
positivity in hospital patients.30 However, the routine 
use of radiologic and serologic examinations may be less 
applicable in clinical practice. The implementation of 
triage could be an easy method to monitor patients in 
this setting of care.
The ONCOVID study provides several important 
findings. First, our data confirm the relatively low inci-
dence of COVID-19 in patients with cancer. From the 
beginning of the pandemic over a 5-month study pe-
riod—including patients who were not enrolled in the 
study—in total, 16 patients at our institution had a docu-
mented COVID-19 diagnosis, and 2 had a strong clinical 
suspicion of COVID-19. Another important finding is 
that the overall incidences of COVID-19 diagnosis in our 
study population (1%) and antibody positivity (13%) in 
patients with suspect symptoms were similar to those ob-
served in patients who had cancer without suspect symp-
toms (11%). Therefore, data from our study suggest that 
most oncology activities can be safely performed during 
the pandemic. Simple containment measures to reduce 
hospital access can be pursued without compromising 
cancer care delivery.
Our study has some intrinsic limitations. The rel-
atively low rate of COVID-19 diagnosis in our popula-
tion might have been caused by the protective measures 
carried out by patients rather than a reduced risk of 
COVID-19. Because of the inability to perform sero-
logic tests on all patients, the incidence of COVID-19 is 
not supported by secure numerators and denominators 
of infection for this calculation. Nevertheless, the num-
ber of positive cases seems low, suggesting that contain-
ment measures and rapid detection of symptoms with 
triage might help physicians to safely provide oncology 
care. Because of the low observed incidence of COVID-
19, an excessively high number of patients should have 
been evaluated to confirm statistically significant re-
sults. However, the results of case-control comparisons 
suggest there is a superimposable incidence of antibody 
positivity among the 2 groups. Finally, the low number 
of confirmed COVID-19 cases does not allow us to de-
rive considerations on prognostic factors for infection 
and outcomes. The identification of patients who are 
at higher risk for COVID-19 is currently under study 
through the validation of a risk-assessment score in the 
study population (the Milano Policlinico ONCOVID 
score).31
Conclusions
In our experience, the triage process had a positive impact 
on the detection of COVID-19 in patients with cancer. 
The overall incidence of COVID-19 diagnosis and an-
tibody positivity in patients with suspect symptoms was 
similar to that observed in asymptomatic patients. The 
identification of risk factors for COVID-19 in patients 
with cancer is needed to customize treatment and provide 
the best care in the current situation.
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